Absci Corp ABSI
Compounding R&D moat at the intersection of compute and AI.
Management holds this up; Valuation is the soft spot.
| Moat | 2.0 |
| Management | 8.0 |
| Valuation | 1.0 |
| Risk · 10 = lowest | 2.0 |
| Business model | 5.0 |
| Optionality | 7.0 |
The price needs 92.0% growth a year for ten years. The AI thinks 25.0% is achievable, at a 35.0% margin.
The -67% gap shows Absci is heavily overvalued, as 92% required growth to reach 35% margin far exceeds the 25% achievable rate and implies unrealistic expectations priced in.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.
Start the thirty days · no card